Artificial Intelligence
Renalytix Convenes Expert Panel at VA Healthcare Summit
NEW YORK and SALT LAKE CITY, Nov. 10, 2021 (GLOBE NEWSWIRE) — In recognition of National Diabetes Month and concurrent with the launch of KidneyIntelX in the Veterans Health Administration health system, Renalytix (NASDAQ: RNLX) (LSE: RENX) convened a multidisciplinary panel to discuss advances in kidney health through early-stage prognosis and intervention of chronic kidney disease (CKD) in patients with type 2 diabetes. Clinical experts shared patient case studies drawing from their experience adding KidneyIntelX into clinical care. The KidneyIntelX enabled care pathway being implemented in the Mount Sinai Health System is a model that can be used in implementing the new Veterans Health Administration CKD Directive and joint VA and Department of Defense guideline, driving care earlier to prevent progression and kidney failure. The panel event took place at The Institute for Defense and Government Advancement (IDGA) VA Healthcare Summit on Wednesday, October 27, 2021.
The panel, “Breakthrough Diagnostic Approach for Type 2 Diabetes and Early-Stage Chronic Kidney Disease (CKD): Today’s Precise Answer, Tomorrow’s Kidney Health,” included renowned thought leaders who highlighted the importance of early detection and intervention to promote long-term kidney health and improve clinical outcomes in their type 2 diabetes patients.
Commenting on the Summit discussion, panelists said:
Michael J. Donovan, PhD, MD, Chief Medical Officer at Renalytix: “This roundtable discussion provided a unique opportunity for clinical experts to highlight the impact of KidneyIntelX risk assessment on patient-specific management decisions. Their remarks highlighted how KidneyIntelX testing can help address the challenges they face when relying on current clinical tools. The panel also reviewed the practice-changing evidence from recent therapeutic trials. The discussion underscored the importance of a systems approach to managing care for chronic kidney disease patients given the intimate association of cardiovascular and kidney function.”
David Lam, MD, Assistant Professor of Medicine (Endocrinology, Diabetes and Bone Disease) at the Icahn School of Medicine at Mount Sinai and Medical Director at the Mount Sinai Clinical Diabetes Institute, NYC, NY: “As an endocrinologist, I see patients living with diabetes day in and day out. Diabetes care is a team effort. I co-manage diabetic patients with other trained professionals, all working towards the care of patients to help them thrive. KidneyIntelX has helped me to identify patients with early-stage diabetic kidney disease earlier and has enabled me to deploy the right care path, direct care resources and provide treatment guidance based on my patients’ risk level at the right time.”
Joseph Vassalotti, MD, FASN, Clinical Professor of Medicine (Nephrology) at Icahn Mount Sinai and Chief Medical Officer of the National Kidney Foundation, NYC, NY: “13.1 % of the US population has diabetes, most with type 2 diabetes, but about 40% also have low kidney function and/or increased albumin, a type of protein, in the urine. Early risk stratification for these patients with kidney disease informs their care management. KidneyIntelX combines biomarkers and the data from the patients’ health record, to produce a risk score that is easy to understand. For patients, reviewing the results of that risk score helps motivate them to take additional action toward their kidney health that is proportional to the risk. As a nephrologist it helps me think about the types of lifestyle modification, patient engagement, medication management and interdisciplinary care that is optimal for my patients.”
Katherine Tuttle, MD, FASN, FACP, FNKF, Professor of Medicine in Nephrology at the University of Washington, the Executive Director for Research at Providence Health Care, and a Co-Principal Investigator at the Institute for Translational Health Sciences: “KidneyIntelX leads into more effective therapeutic management which should lead to improved outcomes in a value-based system. For example, heart failure and chronic kidney disease occur concomitantly. If we reduce heart failure hospitalization by identifying and managing higher risk patients more effectively, that would be a huge savings to the health care system. If we also prevent cases of kidney failure, and the costs associated with treating patients with kidney failure, we will realize enormous cost savings. The triangulation between diabetes, heart failure and chronic kidney disease accounts for one third of the Medicare budget and this cost is extensive in the veteran population as well.”
As the largest integrated health care network in the United States, the U.S. Department of Veterans Affairs is tasked with providing care to America’s Veterans. One in four veterans have diabetes and many have comorbid conditions including kidney disease. Renalytix is committed to promoting kidney health in veterans by aligning care models that proactively protect kidneys from avertable harm.
About Kidney Disease
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and one out of two people with very low kidney function who are not on dialysis do not know they have CKD.1 Kidney disease is referred to as a “silent killer” because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.
About KidneyIntelX
KidneyIntelX, is a first-of-kind solution that enables early-stage diabetic kidney diseases (DKD) progression risk assessment by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record, or EHR, systems, and employs a proprietary algorithm to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in CKD, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that successfully enables early-stage chronic kidney disease, progression risk assessment. The Company’s lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.
KidneyIntelX is based on technology developed by Mount Sinai faculty and licensed to Renalytix, and is currently utilized in sponsored research by Renalytix at Mount Sinai. Mount Sinai and Mount Sinai faculty, including Dr. Steve Coca and Dr. Girish Nadkarni, have a financial interest in Renalytix. Mount Sinai has representation on the Renalytix Board of Directors.
Sources
1 https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning: the potential benefits, including economic savings, of KidneyIntelX, the potential for KidneyIntelX to receive regulatory approval from the FDA, the commercial prospects of KidneyIntelX, if approved, including whether KidneyIntelX will be successfully adopted by physicians and distributed and marketed, our expectations regarding reimbursement decisions and the ability of KidneyIntelX to curtail costs of chronic and end-stage kidney disease, optimize care delivery and improve patient outcomes. Words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “seeks,” and similar expressions are intended to identify forward-looking statements. We may not actually achieve the plans and objectives disclosed in the forward-looking statements, and you should not place undue reliance on our forward-looking statements. Any forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others: that KidneyIntelX is based on novel artificial intelligence technologies that are rapidly evolving and potential acceptance, utility and clinical practice remains uncertain; we have only recently commercially launched KidneyIntelX; and risks relating to the impact on our business of the COVID-19 pandemic or similar public health crises. These and other risks are described more fully in our filings with the Securities and Exchange Commission (SEC), including the “Risk Factors” section of our annual report on Form 20-F filed with the SEC on October 21, 2021, and other filings we make with the SEC from time to time. All information in this press release is as of the date of the release, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.
Media Contacts:
United States:
Jennifer Moritz
Zer0 to 5ive for RenalytixAI
(917) 748-4006
[email protected]
Outside of the United States:
Walbrook PR Limited
Paul McManus / Lianne Cawthorne
Tel: 020 7933 8780 or [email protected]
Mob: 07980 541 893 / 07584 391 303
Artificial Intelligence
Fractal Announces Merger of Eugenie.ai to Bolster AI-Powered Climate Solutions
MUMBAI, India, June 26, 2024 /PRNewswire/ — Fractal (www.fractal.ai), a global provider of artificial intelligence and advanced analytics solutions to Fortune 500® companies, today announced the merger of Eugenie AI (Eugenie.ai), an AI company dedicated to providing AI-driven products for climate change and industrial sustainability.
Founded in 2021, Eugenie has established itself as one of the pioneering forces in AI-driven climate solutions. Their clientele includes some of the world’s largest industrial corporations across energy, metals & mining, and other hard-to-abate sectors. Eugenie’s achievements include being featured at the prestigious 2024 Google I/O, being an alum of the Google for Startups: Climate Change accelerator and winning multiple global accolades such as the NASSCOM Emerge 50, Tech30 recognition by YourStory, and the Vedanta Spark Corporate Innovation Challenge. Eugenie has been featured as a key provider by Gartner in its 2023 Market Guide for Energy Management and Optimization Systems & Market Guide for Commercial and Industrial Energy Management and Optimization Systems.
Srikanth Velamakanni, Co-founder, Group Chief Executive & Vice Chairman, Fractal, said, “We are excited to welcome Eugenie back into the Fractal family. Eugenie’s cutting-edge AI technologies and their commitment to combating climate change align perfectly with our vision to leverage AI for social good. Together, we aim to accelerate the development and deployment of innovative solutions that address some of the most pressing environmental challenges of our time. Eugenie’s expertise in serving major industrial clients complements our goal of creating significant value for client in Fortune 100 organizations.”
Dr. Soudip Roy Chowdhury, Founder and CEO, Eugenie AI, said, “Joining forces with Fractal marks a significant milestone for Eugenie. Our shared values and complementary expertise will enable us to scale our impact and continue our mission to drive sustainable industrial transformations. We look forward to working together to create a future where technology and nature coexist harmoniously. By integrating our AI-driven solutions with Fractal’s extensive capabilities, we can offer even greater value to our clients, helping them achieve their sustainability goals.”
The merger of Eugenie reinforces Fractal’s commitment to harnessing the power of artificial intelligence to address global challenges and underscores its dedication to sustainability and innovation. By integrating Eugenie’s expertise in climate-focused AI solutions, Fractal aims to expand its portfolio and deliver even greater value to its clients and communities worldwide.
Eugenie’s focus on providing AI solutions to some of the hardest-to-abate sectors aligns perfectly with Fractal’s vision of driving significant value for large enterprises. This strategic merger will enhance Fractal’s ability to offer comprehensive AI solutions that not only optimize business operations but also contribute to a more sustainable and resilient industrial ecosystem.
For more information, please visit www.fractal.ai and www.eugenie.ai.
About Fractal
Fractal is one of the most prominent providers of Artificial Intelligence to Fortune 500® companies. Fractal’s vision is to power every human decision in the enterprise, and bring AI, engineering, and design to help the world’s most admired companies.
Fractal’s businesses include Crux Intelligence (AI driven business intelligence), Eugenie.ai (AI for sustainability), Asper.ai (AI for revenue growth management), Senseforth.ai (conversational AI for customer service) & Flyfish (generative AI for Sales). Fractal incubated Qure.ai, a leading player in healthcare AI for detecting Tuberculosis and Lung cancer.
Fractal currently has 4500+ employees across 17 global locations, including the United States, UK, Ukraine, India, Singapore, Middle East and Australia. Fractal has been recognized as ‘Great Workplace’ and ‘India’s Best Workplaces for Women’ in the top 100 (large) category by The Great Place to Work® Institute; featured as a leader in Data Engineering services 2024 & Data Science Services 2024 by Information Services Group, Leader in AI and Analytics Services Specialists Peak Matrix Assessment 2021 by Everest Group, Leader in Customer Analytics Service Providers Wave™ 2023 by Forrester Research, Inc.
About Eugenie AI:
Eugenie is a forward-thinking AI company, headquartered in NY, USA dedicated to creating solutions that address climate change and promote industrial sustainability. Leveraging advanced AI technologies, Eugenie empowers organizations to achieve their sustainability goals and contribute to a healthier planet.
View original content:https://www.prnewswire.com/in/news-releases/fractal-announces-merger-of-eugenieai-to-bolster-ai-powered-climate-solutions-302183085.html
Artificial Intelligence
ADOLFO DOMÍNGUEZ PRESENTS HIS NEW FASHION AND FRAGRANCE COLLECTION AT A WORLD FASHION SHOW
The brand intertwines fashion and perfume to create an immersive experience in the olfactory and creative universe
The fashion show, which will take place in Chile, will be broadcast online in 29 countries. It can be followed live on the brand’s website and social media profiles
MADRID, June 26, 2024 /PRNewswire/ — Adolfo Domínguez keeps moving forward in its commitment to bring fashion closer to society. The brand will showcase Ikigai, its autumn-winter 2024 collection, together with a selection of new perfumes in a global fashion show.
The event, which will mix fashion and fragrances, will be streamed live on 27 June at 6 p.m. (Portuguese time) on the brand’s website, accessible from 29 countries around the world, as well as through Mega, the main television channel in Chile, and Movistar+, in Spain. The event will also be broadcast on the company’s profiles on social media.
Adolfo Dominguez will showcase its fashion and perfume collections from the La Moneda cultural centre in Santiago de Chile, where it will create an immersive experience with artistic performances and music developed exclusively for the occasion. Attendees will have the opportunity to experience first-hand the essence and innovation that define Adolfo Dominguez, consolidating its presence and relevance in the Latin American market.
“Clothes matter. It is our second skin. Perfume is the trace we leave as we walk by. With each new collection, we explore our creativity and out contribution to society as a brand- why should we limit it to a privileged few in a room?” states Patricia Alonso, Corporate Director of Marketing and Communication at Adolfo Domínguez.
Ikigai, a Japanese concept that invites each person to go in search of their vital purpose, is the driving force behind Adolfo Domínguez’s autumn-winter 2024 collection: a selection of garments designed to liberate oneself. The result is a collection designed to be lived, with garments that are born to make people understand that beauty and happiness reside in the little things.
The fashion show will be streamed on www.adolfodominguez.com and on the brand’s profiles on social media (Youtube, Instagram and Facebook). In Latin America, the fashion show can also be seen on Mega, one of the main Chilean television channels.
Photo – https://mma.prnewswire.com/media/2444915/Adolfo_Dominguez.jpgLogo – https://mma.prnewswire.com/media/2445072/Adolfo_Dominguez_logo.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/adolfo-dominguez-presents-his-new-fashion-and-fragrance-collection-at-a-world-fashion-show-302179102.html
TORONTO, NECKARSULM, Germany and NORTHAMPTON, UK, June 26, 2024 /PRNewswire/ — Darwin CX and dsb deepen their alliance as Darwin CX becomes a shareholder of dsb. The Canadian company’s investment in dsb expands Darwin CX into the UK and European market and dsb becomes part of the pioneering Darwin CX family. The strategic partnership marks a significant milestone for Darwin CX and dsb, both leading providers of SaaS solutions and services for publishers.
The most remarkable aspect of this union is the parallel trajectories of these formidable companies prior to the partnership. Darwin CX and dsb’s fly ecosystem both launched in 2018 with the common goal of modernizing the publishing industry, which had become heavily reliant on outdated practices and legacy systems. Each company was on an independent mission to create an ecosystem of tools and solutions that would allow publishers to thrive in a fast-paced, data-driven, digital-first marketplace.
Best practices from North America meet European recipes for success
“While Darwin CX developed a platform for the needs of a North American publishing audience, the dsb fly ecosystem offers its European customers a variety of tools to increase acquisition, maximize customer lifetime value and reduce costs and effort,” explains Liam Lynch, CEO of Darwin CX.
Broader range of resources and features
Darwin CX and dsb are process experts in the publishing environment. “We know the industry’s workflows inside out and have the same vision. Now, as subscription professionals, we are joining forces and offering our customers scalable solutions that enable them to tap into new revenue streams in a dynamic market,” emphasizes Olaf Bendt, CEO of the dsb Group. “Our customers benefit from an even broader range of resources and features.”
Next generation sales and marketing solutions
Publishers are battling dwindling attention spans and declining engagement. dsb and Darwin CX offer the publishing industry new, powerful tools for even more accurate content offers, prices and subscription conditions. All of this is based on data-driven, AI-supported personalization, which offers publishers new insights into their customers’ engagement and launches targeted measures to increase loyalty.
Prioritizing business continuity
“To meet the growing needs of our customers, dsb will expand their fly back-end infrastructure while integrating some of Darwin CX’s key marketing and data management tools. Of course, business continuity will be maintained for both our European and North American clients. We will offer our clients the best of both worlds without disrupting their day-to-day business,” emphasizes Alex Münch, COO at dsb Group.
Solutions for digital and printed content
Darwin CX and dsb are united by a focus on maximizing recurring revenue, seamless integration of online and offline solutions, and a fundamental belief in customer centricity. “The DNA of both companies is the publishing industry. That’s why, together with dsb, we are focusing on customized solutions for printed and digital Content”, stresses Michael Smith, Darwin CX Co-Founder and Chief Technology Officer.
About Darwin CX
Darwin CX is a transformative SaaS and services platform at the leading edge of the subscription and membership economies. Founded in Toronto, Canada, Darwin CX assists brands accelerate acquisition and retention—and increase loyalty—through innovative and customized check-out pages, targeted audience offerings, real-time A/B testing and best-in-class analytics, paywall and customer data platform (CDP). The Darwin CX platform enables clients to have complete freedom and control over customer data in order to tailor the best possible customer experiences. Over 140 well-known publishers and more than 300 brands in the USA, Canada and Australia rely on Darwin CX for their data and subscription management needs. Led by CEO, Liam Lynch, CTO, Michael Smith, COO, Cat Kiernan and President, Cary Zel, Darwin CX is backed by a group of growth equity investors with a common theme of disrupting industries and driving digital innovation including First Ascent Ventures, New Era Capital Partners and Felicitas Global Partners.
About dsb
With dsb fly, the dsb group develops and operates Europe’s leading subscription ecosystem for the publishing industry. Key players in the media industry have been relying on dsb’s holistic and customer-centric monetization solutions for over 50 years. Whether lifestyle products, seminars, events, digital or print titles – the dsb fly ecosystem offers media companies a customized 360-degree customer view of print and digital consumption. This all-round view is the basis for highly individualized worlds of experience and high customer loyalty. dsb fly manages customer relationships along the entire customer life cycle and maximizes subscription retention and sales with accurate subscription offers and highly individualized worlds of experience.
TAGGED WITH: Darwin CX, Liam Lynch, Michael Smith, Cary Zel, dsb, dsb.net, Olaf Bendt, Alex Münch
To find out if Darwin CX and dsb are right for your international business, contact [email protected]
Photo – https://mma.prnewswire.com/media/2447856/Darwin_CX_LLC_Darwin_CX_Broadens_Global_Reach_via_Strategic_Part.jpg
View original content:https://www.prnewswire.co.uk/news-releases/darwin-cx-broadens-global-reach-via-strategic-partnership-with-dsb-302182339.html
-
Artificial Intelligence5 days agoTech Developers Pioneering AI Tools to Revolutionize Future Productivity and Logistics
-
Artificial Intelligence5 days ago2024 World Intelligence Expo kicks off in Tianjin
-
Uncategorized5 days agoDyspareunia Treatment Market to Hit $1,035.4 million by 2031, at a CAGR of 4.6%, says Coherent Market Insights
-
Artificial Intelligence5 days ago
2024 World Intelligence Expo Begins with a Grand Opening in Tianjin
-
Artificial Intelligence5 days agoEenovance Showcases Comprehensive Product Solutions at Intersolar Europe 2024
-
Artificial Intelligence5 days agoKidoodle MiniBox A1: Sowing Seeds of Imagination for Kids
-
Artificial Intelligence5 days ago
Key Tech Stocks Optimizing AI Usability and Infrastructure for a $20-Trillion Future
-
Artificial Intelligence5 days ago
Tianjin Advances with AI
